At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 273 enrolled
Drug / intervention
E6011 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Dose Response Study of E6011 in Subjects With Rheumatoid Arthritis Inadequately Responding to Methotrexate
In Brief
A Phase 2 clinical trial evaluating E6011 and Placebo for Rheumatoid Arthritis. Completed, enrolled 273 participants across 90 sites.
Detailed Summary
This study is a multicenter, randomized, double-blind, placebo-controlled, parallel-group comparison study in rheumatoid arthritis participants inadequately responding to methotrexate.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartOct 2016
First PostedNov 2016
Primary CompletionFeb 2018
Study CompletionSep 2019
TodayJul 2026
First PostedNov 9, 2016
Enrollment StartOct 20, 2016
Primary CompletionFeb 28, 2018
Study CompletionSep 17, 2019
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 9.6 years ago
Interventions
E6011drug
subcutaneous administration
Placebodrug
subcutaneous administration